Related Experiment Video

Updated: May 8, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.1K

Cardiogenic Shock: Protocols, Teams, Centers, and Networks

Alex F Warren1,2, Carolyn Rosner3, Raghav Gattani3

  • 1South-East Scotland School of Anaesthesia Edinburgh, UK.

US Cardiology
|December 25, 2024
PubMed

Insights

Improving cardiogenic shock (CS) outcomes requires a coordinated approach. Implementing multidisciplinary shock teams and networked care facilities can reduce mortality and improve patient outcomes.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Health Systems Science

Background:

  • Cardiogenic shock (CS) continues to have high mortality rates.
  • Delays in CS recognition and treatment access contribute to poor outcomes.
  • Multidisciplinary 'shock team' approaches are increasingly recommended for CS management.

Purpose of the Study:

  • To review the benefits of a networked approach to cardiogenic shock care.
  • To discuss team-based and protocolized CS management strategies.
  • To explore the potential benefits, challenges, and opportunities of integrated CS care systems.

Main Methods:

  • This is a narrative review.
  • The review synthesizes existing evidence on CS management strategies.
  • It discusses the implementation of 'shock teams' and 'shock networks'.

Main Results:

  • A volume-outcome relationship is observed in CS care.
  • Networked care models and 'shock hubs' offer opportunities for improved and equitable CS treatment.
  • Team-based and protocolized management can enhance patient outcomes.

Conclusions:

  • Coordinated, multidisciplinary, and networked approaches are crucial for improving cardiogenic shock outcomes.
  • Implementing 'shock teams' and 'shock networks' can address current challenges in CS care.
  • Further development of these systems holds promise for reducing CS mortality.

Keywords:
Cardiogenic shockacute MIpercutaneous coronary interventionshock networksshock teams

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K
The Intra-Aortic Balloon Pump06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

20.6K

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
719
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
63
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
259
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
37
Imbalances in Cardiac Output01:23

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
1.2K